This study aimed to validate BRAFV600E/RNF43 co-mutations as predictive biomarkers of benefit to anti-EGFR/BRAF therapy, using clinical data from the Flatiron Health-Foundation Medicine real-world clinico-genomic metastatic colorectal cancer database. This evidence concerns the gene EGFR and metastatic colorectal cancer.